Cuba promotes more than a hundred clinical trials in 2023
Havana, Sep 12 (RHC) Cuba is promoting this year 104 clinical trials linked to cancer, infections and Covid-19.
In the meeting held this Tuesday by Cuban President Miguel Díaz-Canel with health experts, it was reported that work is being done on more than 30 trials linked to cancer, more than 40 to the clinic, about 20 related to Covid-19 and more than 10 in the area of infections, among others.
Regarding the distribution of these clinical trials, 60 deal with biological products and 18 natural products, 17 are vaccines, five revolve around medical equipment and devices, and others are chemical-pharmaceutical based.
According to Dr. Amaylid Arteaga, director of the National Clinical Trials Coordinating Center, due to the radical changes caused by the impact of Covid-19, today we can speak of a before and after in concepts and actions.
She pointed out that in the National Action Protocol, 85 percent of the products are from Cuban industry, and that regulatory innovation has been achieved in order to shorten times without affecting the quality of clinical data.
Arteaga highlighted that at the center of this activity are researchers and their nursing, pharmaceutical, and staff from other disciplines. She explained it is a system of shared responsibilities, based on good clinical practices, which include health institutions and research ethics committees, promoters and monitors, and regulatory authorities.
Among the current clinical trials are the one linked to NeuroEPO, related to Alzheimer's and including about 500 patients from several provinces, and NeuroEPO, linked to Ataxia and with more than 70 people included.
The specialist also mentioned the Jusvinza, a study related to Rheumatoid Arthritis in about 300 patients; the pneumococcal vaccine, with an intervention in the central province of Cienfuegos with more than a thousand children vaccinated, and the Cimavax-EGF in a lung cancer preventive scenario, in which more than 30 patients are included. (Source: PL)
